Document is current
Any future updates will be listed below
-
Authors
Ellingsen, Espen Basmo http://orcid.org/0000-0002-0235-1184
Bounova, Gergana
Kerzeli, Iliana
Anzar, Irantzu
Simnica, Donjete
Aamdal, Elin
Guren, Tormod
Clancy, Trevor
Mezheyeuski, Artur
Inderberg, Else Marit
Mangsbo, Sara M.
Binder, Mascha
Hovig, Eivind
Gaudernack, Gustav
-
Funding
Funding for this research was provided by:
Ultimovacs ASA
- License Information
-
More Information
Article History
Received: 10 August 2022
Accepted: 1 September 2022
First Online: 11 September 2022
Declarations
:
: The study participants provided written informed consent prior to enrolment. The trial was conducted in accordance with the ethical principles of the Declaration of Helsinki and the International Conference on Harmonization of Good Clinical Practice and approved by an independent ethics committee and the appropriate national and institutional review boards (REK reference 2014/421).
: Not applicable.
: EBE, SMM, and GG are employees of Ultimovacs ASA or Ultimovacs AB. GG, SMM, and EMI are shareholders in Ultimovacs ASA. GG and EMI are inventors of the UV1 patent. SMM is the founder and shareholder of Immuneed AB, Vivologica AB, and Strike Pharma AB, none of which has had any role in this work. Other authors declare that they have no conflicts of interest.
